Table 3.

Number and Proportion of REGARDS Participants Receiving Osteoporosis Therapies* by FRAX 10-Year Hip Fracture Risk**, Sex, and Race

Estimated 10-year hip fracture risk	Caucasian n = 14,958		African American n = 9,825
	Men† n = 7,339	Women† n = 7,619	Men‡ n = 3,545	Women† n = 6,280
<1.4%	15/3,281 (0.4%)	174/2,897 (6%)	10/3,004 (0.3%)	145/4,708 (3%)
1.4–<3.0%	16/1,478 (1%)	213/1,697 (13%)	2/444 (0.5%)	69/942 (7%)
3.0–<5.0%	20/1,024 (2%)	154/926 (17%)	0/72 (0%)	37/417 (9%)
5.0–<10.0%	20/776 (3%)	222/1,196 (19%)	0/20 (0%)	15/167 (9%)
≥10.0%	8/240 (3%)	235/903 (26%)	0/5 (0%)	1/46 (2%)

Data shown as number treated/number eligible (%)

*Including alendronate, risedronate, ibandronate, teriparatide, raloxifene, or calcitonin

**Hip fracture risk estimates were computed using the WHO FRAX tool with body mass index (http://shef.ac.uk/FRAX)

†p < 0.001 for column trend

‡p = 0.96